(Q36615272)

English

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

scientific article published on September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Zidan

1

1 reference

Europe PubMed Central

15 August 2017

I Dashkovsky

2

1 reference

Europe PubMed Central

15 August 2017

C Stayerman

3

1 reference

Europe PubMed Central

15 August 2017

W Basher

4

1 reference

Europe PubMed Central

15 August 2017

C Cozacov

5

1 reference

Europe PubMed Central

15 August 2017

A Hadary

6

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

93

1 reference

Europe PubMed Central

15 August 2017

552-556

1 reference

Europe PubMed Central

15 August 2017

5

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602738

0 references

An overview of HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

30 September 2017

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

20 September 2018

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

20 September 2018

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

20 September 2018

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361603

20 September 2018

Phase I and II clinical trials of trastuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intra—and extra—tumorous samples from 3 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16106267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602738

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36615272&oldid=1640746859"